Previous 10 | Next 10 |
Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- MannKind Co...
2024-02-14 19:49:34 ET Summary MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a competing form...
2024-02-12 22:49:38 ET Summary Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a s...
2024-02-01 10:45:00 ET Summary MoneyShow presents top investment ideas for 2024 from their contributors. This year’s edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations tha...
2024-01-10 16:52:44 ET Gainers: MannKind Corporation ( NASDAQ: MNKD ) +5% . Kandi Technologies Group ( KNDI ) +5% . Outset Medical ( OM ) +4% . HWH International ( HWH ) +3% . Atea Pharmaceuticals ( AVIR ) +3% . Losers:...
2024-01-02 06:35:54 ET MannKind ( NASDAQ: MNKD ) has sold a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare in exchange for up to $200M as part of a royalty purchase deal . The biopharmaceutical firm is entitled to a 10% royal...
Sagard Healthcare purchased a 1% royalty in Tyvaso DPI ® net sales Purchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) ann...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Ex...
2023-11-25 03:20:10 ET Summary Latest revenue results are not favorable for MannKind nor United. MannKind needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. United has been an unreliable partner for future use of MannKind's technology...
2023-11-10 17:00:46 ET Gainers: StoneCo ( STNE ) +6% . Hologic ( HOLX ) +4% . Cardlytics. ( CDLX ) +3% . MannKind Corporation ( MNKD ) +3% . Confluent ( CFLT ) +2% . Losers: Chijet Motor Company ( CJET ) -6% ...
News, Short Squeeze, Breakout and More Instantly...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Tim...
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteers Enrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announc...